Vaxart, Inc. (VXRT) is a clinical-stage biotechnology company that focuses on developing oral vaccines. The company uses its proprietary oral vaccine platform to develop vaccines for a variety of diseases, including influenza, norovirus, and COVID-19. Vaxart's platform uses adenovirus-based vectors to deliver the vaccine antigen directly to the mucosa of the gastrointestinal tract. This approach has the potential to provide more robust immune responses than traditional injectable vaccines.
Vaxart's lead vaccine candidate is an oral tablet vaccine for COVID-19. The vaccine is currently in Phase 2 clinical trials and has shown promising results in preclinical studies. The company is also developing oral vaccines for influenza and norovirus.
Vaxart has partnerships with several organizations, including the US Army Medical Research Institute of Infectious Diseases and Emergent BioSolutions, to develop and manufacture its vaccines. The company is headquartered in South San Francisco, California, and was founded in 2004.
Vaxart, Inc. (VXRT) is a clinical-stage biotechnology company that focuses on developing oral vaccines. The company uses its proprietary oral vaccine platform to develop vaccines for a variety of diseases, including influenza, norovirus, and COVID-19. Vaxart's platform uses adenovirus-based vectors to deliver the vaccine antigen directly to the mucosa of the gastrointestinal tract. This approach has the potential to provide more robust immune responses than traditional injectable vaccines.